Recently, we have described for the first time that siRNA-mediated knockdown of RUNX2 increases adriamycin (ADR) sensitivity of p53-wild-type osteosarcoma cells through the activation of p53 family-dependent cell death pathway [19, 20]. This evidence concerns the gene TP53 and osteosarcoma.